Shuai Zhen

Dr. Shuai Zhen


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SZShuai Zhen
Shuai Zhen
LHLing Hua
Ling Hua
YTY. Takahashi
Y. Takahashi
SNS. Narita
S. Narita
YLYun-Hui Liu
Yun-Hui Liu
YLYan Li
Yan Li

11 October 2022 in Journal of Medical Virology
Verified
Journal Article
Closed access
SZShuai Zhen
Shuai Zhen
RQRong Qiang
Rong Qiang
JLJiaojiao Lu
Jiaojiao Lu
XTXiaoqian Tuo
Xiaoqian Tuo
XYXiling Yang
Xiling Yang
XLXu Li
Xu Li

20 January 2022 in Journal of Clinical Monitoring and Computing
Verified
Journal Article
Open access
PDF file
XJXiaofeng Jiang
Xiaofeng Jiang
YZYanhong Zhu
Yanhong Zhu
SZShuai Zhen
Shuai Zhen
LWLei Wang
Lei Wang
This study aimed to determine the predictive relevance of mechanical power in the clinical outcomes (such as ICU mortality, hospital mortality, 90-day mortality, length of ICU stay, and number of ventilator-free days at day 28) of neurocritical patients. This is a retrospective cohort analysis of an open-access clinical database known as MIMIC–III. The study included patients who had sustained an acute brain injury and required invasive ventilation for at least 24 h. Demographic parameters, disease severity scores (Glasgow coma scale), comorbidities, vital signs, laboratory parameters and ventilator parameters were collected within the first 24 h of ICU admission. The main outcome was the relationship between MP and ICU mortality. A total of 529 patients were selected for the study. The critical value of MP was 12.16 J/min, with the area under the curve (AUC) of the MP was 0.678 (95% CI 0.637–0.718), and compared to the GCS scores, the MP performed significantly better in discrimination (DeLong’s test: p < 0.001). Among these patients elevated MP was associated to higher ICU mortality (OR 1.11; 95% CI 1.06–1.17; p < 0.001), enhanced the risk of hospital mortality, prolonged ICU stay, and decreased the number of ventilator-free days. In the subgroup analysis, high MP was associated with ICU mortality regardless of ARDS (OR 1.01, 95% CI 1.00–1.02, p = 0.009; OR 1.01, 95% CI 1.00–1.02, p = 0.018, respectively) or obesity (OR 1.01, 95% CI 1.00–1.02, p = 0.012; OR 1.01, 95% CI 1.01–1.02, p < 0.001, respectively). In neurocritical care patients undergoing invasive ventilation, elevated MP is linked to higher ICU mortality and a variety of other clinical outcomes.

1 February 2021 in Molecular Immunology
Verified
Journal Article
Closed access
SZShuai Zhen
Shuai Zhen
RQRong Qiang
Rong Qiang
JLJiaojiao Lu
Jiaojiao Lu
XTXiaoqian Tuo
Xiaoqian Tuo
XYXiling Yang
Xiling Yang
XLXu Li
Xu Li

1 February 2021 in Current Gene Therapy
Verified
Journal Article
Closed access
PDF file
SZShuai Zhen
Shuai Zhen
RQRong Qiang
Rong Qiang
JLJiaojiao Lu
Jiaojiao Lu
XTXiaoqian Tuo
Xiaoqian Tuo
XYXiling Yang
Xiling Yang
XLXu Li
Xu Li
Background: Radiation-induced lung injury (RILI) is lacking effective therapeutic strategies. In this study, we conducted TGF-β1-based CRISPR/Cas9 gene therapy for RILI. Objectives: Mouse lungs were irradiated with a single-dose of 20-Gy gamma rays followed by intravenous administration of Ad-CRISPR-TGF-β1 or Ad- CRISPR-Null. Methods: Haematoxylin and eosin staining, as well as Masson staining were performed to observe lung morphology. Albumin and IgM concentrations in bronchoalveolar lavage fluid were measured by ELISA. Cytokine levels were measured using ELISA and/or real-time PCR with terminal deoxynucleotidyl transferase mediated nick-end labelling. Results: Ad-CRISPR-TGFβ1 improved histopathological and biochemical markers of lung injury, reduced secretion and expression of inflammatory cytokines, and inhibited progression of fibrosis. Importantly, the SK1/S1P axis—which is known to play a key role via S1P1 in TGF-β1-dependent S1PR pattern remodelling—is responsible for promoting fibrosis. Conclusion: Our results indicate novel insights for RILI therapy.

10 May 2023 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
BCBo Cai
Bo Cai
SCShixue Chang
Shixue Chang
YTYuhan Tian
Yuhan Tian
SZShuai Zhen
Shuai Zhen
Hepatitis B virus (HBV) infection remains a global health challenge. Despite the availability of effective preventive vaccines, millions of people are at risk of cirrhosis and hepatocellular carcinoma. Current drug therapies inhibit viral replication, slow the progression of liver fibrosis and reduce infectivity, but they rarely remove the covalently sealed circular DNA (cccDNA) of the virus that causes HBV persistence. Alternative treatment strategies, including those based on CRISPR/cas9 knockout virus gene, can effectively inhibit HBV replication, so it has a good prospect. During chronic infection, some virus gene knockouts based on CRISPR/cas9 may even lead to cccDNA inactivation. This paper reviews the progress of different HBV CRISPR/cas9, vectors for delivering to the liver, and the current situation of preclinical and clinical research.